Supplier profile
Novartis Pharma GmbH
Every public-sector award we hold for this supplier, across Austria and Germany, from 5 Jan 2009 to 3 Sept 2026.
Awards won
89
all time
Attributed value
€1.9m
29 shared, unvalued
Buyers
39
public bodies
Active
2009–2026
first to latest award
Awards by year
Who they win from
| Buyer | Awards | Value |
|---|---|---|
| AOK Rheinland/Hamburg - Die Gesundheitskasse | 11 | not attributable |
| AOK Baden-Württemberg | 9 | not attributable |
| DAK-Gesundheit | 9 | €2 |
| IKK classic | 7 | €4 |
| AOK Sachsen - Anhalt | 4 | €4 |
| AOK Bayern - Die Gesundheitskasse | 3 | not attributable |
| AOK Rheinland/Hamburg – Die Gesundheitskasse | 3 | €1 |
| GWQ ServicePlus AG | 3 | €2 |
| PBMG eG | 3 | not attributable |
| AOK Bayern - Die Gesundheitskasse | 2 | not attributable |
What they win
Awards
Showing 1–25 of 89 awards we hold
- Germany – Pharmaceutical products – Gewährung von Rabatten bei der Abgabe von Fertigarzneimitteln mit der Wirkstoffkombination Valsartan und Sacubitril (ATC-Code: C09DX04) ↗AOK Sachsen - Anhalt€1awarded 3 Sept 2026
- Gewährung von Rabatten bei der Abgabe von Fertigarzneimitteln mit der Wirkstoffkombination Valsartan und Sacubitril (ATC-Code: C09DX04) ↗AOK Sachsen - Anhalt€1awarded 2 Sept 2026
- Germany – Pharmaceutical products – Arzneimittelrabattvereinbarung gemäß § 130c Abs. 1 SGB V i. V. m § 130a Abs. 8 SGB V zum Wirkstoff Erenumab ↗AOK Baden-Württembergshared awardawarded 19 Aug 2026
- Germany – Pharmaceutical products – Abschluss eines nicht-exklusiven Rabattvertrages gemäß §§ 130a Abs. 8 und 130c Abs. 1 SGB V zwischen der IKK classic und der Novartis Pharma GmbH zu Rhapsido ↗IKK classic€1awarded 28 May 2026
- Abschluss eines nicht-exklusiven Rabattvertrages gemäß §§ 130a Abs. 8 und 130c Abs. 1 SGB V zwischen der IKK classic und der Novartis Pharma GmbH zu Rhapsido ↗IKK classic€1awarded 27 May 2026
- Germany – Pharmaceutical products – Bekanntmachung vergebener Aufträge nach §130 a Abs. 8 SGB V und §130 c SGB V zu dem Präparat Remibrutinib (Rhapsido) ↗GWQ ServicePlus AG€1awarded 27 May 2026
- Germany – Pharmaceutical products – Gewährung von Rabatten bei der Abgabe von Fertigarzneimitteln mit dem Wirkstoff Erenumab (ATC-Code: N02CD01) ↗AOK Sachsen - Anhalt€1awarded 5 May 2026
- Gewährung von Rabatten bei der Abgabe von Fertigarzneimitteln mit dem Wirkstoff Erenumab (ATC-Code: N02CD01) ↗AOK Sachsen - Anhalt€1awarded 4 May 2026
- Germany – Pharmaceutical products – Bekanntmachung vergebener Aufträge nach § 130 c SGB V zu dem Arzneimittel Inclisiran (Leqvio) ↗GWQ ServicePlus AG€1awarded 25 Feb 2026
- Germany – Pharmaceutical products – Arzneimittelvergaben zum 01.01.2026 und 01.07.2026 ↗PBMG eGawarded 29 Dec 2025
- Germany – Pharmaceutical products – Abschluss eines nicht-exklusiven Rabattvertrages gemäß § 130a Abs. 8 SGB V zwischen der IKK classic und der Novartis Pharma GmbH zu Kesimpta ↗IKK classic€1awarded 21 Oct 2025
- Abschluss eines nicht-exklusiven Rabattvertrages gemäß § 130a Abs. 8 SGB V zwischen der IKK classic und der Novartis Pharma GmbH zu Kesimpta ↗IKK classic€1awarded 20 Oct 2025
- Germany – Pharmaceutical products – Arzneimittelrabattvereinbarung gemäß § 130a Abs. 8 SGB V zum Wirkstoff Ofatumumab ↗AOK Baden-Württembergshared awardawarded 13 Aug 2025
- Ex-Ante-Transparenzbekanntmachung § 130a Abs. 8 SGB V Kesimpta (R) Wirkstoff: Ofatumumab ATC-Code: L04AG12 ↗AOK Bayern - Die Gesundheitskasseawarded 24 Jul 2025
- Germany – Pharmaceutical products – Arzneimittelrabattvereinbarung gemäß § 130c Abs. 1 SGB V i. V. m. § 130a Abs. 8 SGB V zum Wirkstoff Secukinumab ↗AOK Baden-Württembergshared awardawarded 18 Jun 2025
- Germany – Pharmaceutical products – Abschluss von nicht exklusiven Rabattverträgen gemäß § 130a Abs. 8 SGB V zu Arzneimitteln (Open-House-Verfahren) ↗AOK Baden-Württembergshared awardawarded 4 Jun 2025
- Ex-Ante-Transparenzbekanntmachung § 130c Abs. 1 SGB V Cosentyx (R) Wirkstoff: Secukinumab ATC-Code: L04AC10 ↗AOK Bayern - Die Gesundheitskasseawarded 15 May 2025
- Germany – Pharmaceutical products – Arzneimittelrahmenrabattvertrag gemäß § 130c Absatz 1 des Fünften Sozialgesetzbuchs - Aimovig (Wirkstoff: Erenumab), ATC N02CD01 ↗DAK-Gesundheit€1awarded 15 Apr 2025
- Aimovig (Wirkstoff: Erenumab), ATC N02CD01 ↗DAK-Gesundheit€1awarded 11 Apr 2025
- Vereinbarung gemäß § 130c SGB V zu dem Arzneimittel Aimovig mit dem Wirkstoff Erenumab ↗AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringenawarded 2 Apr 2025
- § 130c Abs. 1 SGB V Entresto (R) Wirkstoffkombination: Sacubitril und Valsartan ATC-Code: C09DX04 ↗AOK Bayern - Die Gesundheitskasseawarded 20 Feb 2025
- Germany – Pharmaceutical products – Arzneimittelvergaben zum 01.01.2025 und 01.07.2025 ↗PBMG eGawarded 9 Feb 2025
- Germany – Pharmaceutical products – Vertragsabschluss zum Arzneimittelwirkstoff Erenumab, Verkaufsname: Aimovig(R), Unternehmen: Novartis Pharma GmbH ↗AOK Rheinland/Hamburg - Die Gesundheitskasseawarded 25 Sept 2024
- Vertragsabschluss zum Arzneimittelwirkstoff Erenumab, Verkaufsname: Aimovig(R), Unternehmen: Novartis Pharma GmbH ↗AOK Rheinland/Hamburg - Die Gesundheitskasseawarded 24 Sept 2024
- Arzneimittelbezeichnung:
Ilaris®
Wirkstoff:
Canakinumab
ATC-Code:
L04AC08 ↗AOK Bayern - Die Gesundheitskasseawarded 23 Sept 2024
Possibly the same organisation
These entries differ from this one only by legal form or a bracketed qualifier, so they may be the same organisation — or a different registered company of the same name. They are kept apart on purpose: the figures on each page are per legal entity and are never combined.
- Novartis Pharma264 awards
- Novartis Pharma SAS77 awards
- Novartis Pharma SA29 awards
- Novartis Pharma NV10 awards
- Novartis Pharma SpA3 awards
- Novartis Pharma (montant renseigné ci-dessous correspondant à la 1ère période d'exécution)1 award
- NOVARTIS PHARMA SAS ( Rang 1)1 award
- NOVARTIS PHARMA SAS ( Rang 2)1 award
Bidding against them?
Get new tenders in their space in a daily digest, scored against your own capability — plus the full notice behind each of these awards, with the documents and contacts it published.
Start 7-day free trialHow this profile is built
Awards are collected from official public procurement notices and deduplicated so one procurement counts once. Supplier names are grouped across their published spellings: case and punctuation are ignored, and “Ltd” is treated as optional because buyers routinely leave it off. Everything else that marks a different organisation is kept — an LLP, a plc, a CIC and a Teoranta are separate businesses from a Ltd of the same name, as are a parent and a named subsidiary, and none of them are merged here. Where another entry differs from this one only by legal form or a bracketed qualifier it is listed above as possibly the same organisation — a hint for the reader, never a merge: figures are per legal entity and never combined. Value is attributed only where the notice is explicit: the supplier's own itemised amount, or the whole value where they were the sole named supplier. Awards naming several suppliers without a published split are counted and marked shared, never valued, and a framework ceiling is never treated as money any one appointed supplier won. Sterling and euro are never added together. The linked source notice is authoritative.
Company pages are for organisations. If this page profiles you as an individual — a sole trader or an individual contractor — you can ask for it to be withheld: see how.